Trastuzumab biosimilar - Pfizer

Drug Profile

Trastuzumab biosimilar - Pfizer

Alternative Names: PF-05280014; PF-5280014; Trastuzumab - Pfizer

Latest Information Update: 22 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 09 Feb 2017 Pfizer suspends participant recruitment in a phase-III trial in Breast cancer (First-line therapy, Metastatic disease) in Hungary, the Czech Republic, Japan, Portugal, Poland, Romania, Spain, South Korea, Philippines, Ukraine, Russia, Greece, Chile, South Africa, USA, Argentina, Brazil, India, Latvia, Mexico, Peru, Serbia, Slovakia, Thailand, Turkey (NCT01989676)
  • 01 Mar 2016 Pfizer completes the REFLECTION B327-04 trial in Breast cancer (Combination therapy, Early-stage disease, Neoadjuvant therapy) in US, Belarus, Italy, Hungary, Serbia, Slovakia, Ukraine, Poland, Czech Republic and Russia (NCT02187744/ EudraCT2013-004679-11)
  • 25 Nov 2014 Phase-III clinical trials in Breast cancer (First-line therapy, Metastatic disease) in USA, Romania and India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top